Skip to main content
SpringerLink
Log in

Programmatic Screening for Colorectal Cancer: The COLONPREV Study

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The COLONPREV study is an ongoing multicenter, nationwide, randomized controlled trial aimed at evaluating the efficacy of once-only colonoscopy and biennial fecal immunochemical testing with respect to the reduction of CRC-related mortality at 10 years in average-risk colorectal cancer screening population. Following a pragmatic approach, this study may contribute to establishing the most cost-effective strategy in a programmatic, population-based setting. In this review, we report the results obtained at the first screening round, as well as others achieved in nested evaluations using the COLONPREV dataset with the aim of clarifying some controversial issues on the different strategies of colorectal cancer screening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917.

    Article  CAS  PubMed  Google Scholar 

  2. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–160.

    Article  PubMed  Google Scholar 

  3. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–1607.

    Article  CAS  PubMed  Google Scholar 

  4. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633.

    Article  PubMed  Google Scholar 

  5. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103:1541–1549.

    Article  PubMed  Google Scholar 

  6. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med. 2010;7:e1000370.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Segnan N, Patnick J, von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: Publications Office of the European Union; 2010.

    Google Scholar 

  8. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer. 2008;44:2254–2258.

    Article  CAS  PubMed  Google Scholar 

  9. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135:82–90.

    Article  PubMed  Google Scholar 

  10. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009;100:1103–1110.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62–68.

    Article  CAS  PubMed  Google Scholar 

  12. Segnan N, Senore C, Andreoni B, et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology. 2007;132:2304–2312.

    Article  PubMed  Google Scholar 

  13. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706.

    Article  CAS  PubMed  Google Scholar 

  14. Castells A, Castellvi-Bel S, Balaguer F. Concepts in familial colorectal cancer: where do we stand and what is the future? Gastroenterology. 2009;137:404–409.

    Article  PubMed  Google Scholar 

  15. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.

    Article  CAS  PubMed  Google Scholar 

  16. Jover R, Herraiz M, Alarcon O, et al. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy. 2012;44:444–451.

    Article  CAS  PubMed  Google Scholar 

  17. Parra-Blanco A, Nicolas-Perez D, Gimeno-Garcia A, et al. The timing of bowel preparation before colonoscopy determines the quality of cleansing, and is a significant factor contributing to the detection of flat lesions: a randomized study. World J Gastroenterol. 2006;12:6161–6166.

    PubMed Central  PubMed  Google Scholar 

  18. AndreuGarcia M, Marzo M, Mascort J, et al. Prevention of colorectal cancer. Gastroenterol Hepatol. 2009;32:137–139.

    Article  Google Scholar 

  19. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–895.

    Article  CAS  PubMed  Google Scholar 

  20. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–899.

    Article  CAS  PubMed  Google Scholar 

  21. Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol. 2009;25:422–427.

    Article  PubMed  Google Scholar 

  22. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000;343:162–168.

    Article  CAS  PubMed  Google Scholar 

  23. Lieberman DA, Weiss DG, Harford WV, et al. Five-year colon surveillance after screening colonoscopy. Gastroenterology. 2007;133:1077–1085.

    Article  PubMed  Google Scholar 

  24. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.

    Article  PubMed  Google Scholar 

  25. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer. 2011;104:1779–1785.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670–674.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–255.

    Article  PubMed  Google Scholar 

  28. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med. 2000;343:169–174.

    Article  CAS  PubMed  Google Scholar 

  29. Levin TR, Palitz A, Grossman S, et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA. 1999;281:1611–1617.

    Article  CAS  PubMed  Google Scholar 

  30. Read TE, Read JD, Butterly LF. Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl J Med. 1997;336:8–12.

    Article  CAS  PubMed  Google Scholar 

  31. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med. 2005;352:2061–2068.

    Article  CAS  PubMed  Google Scholar 

  32. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial—SCORE. J Natl Cancer Inst. 2011;103:1310–1322.

    Article  PubMed  Google Scholar 

  33. Bretthauer M, Gondal G, Larsen K, et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol. 2002;37:568–573.

    Article  CAS  PubMed  Google Scholar 

  34. Castells A, Bessa X, Quintero E, et al. Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst. 2013;105:878–886.

    Article  PubMed  Google Scholar 

  35. Castells A, Quintero E, Álvarez C, et al. Rate of detection of advanced neoplasms in proximal colon by simulated sigmoidoscopy vs. fecal immunochemical tests. Clin Gastroenterol Hepatol. 2014;12:1708–1716.

  36. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570–1578.

    Article  PubMed  Google Scholar 

  37. Fraser CG, Allison JE, Young GP, Halloran SP. Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening. Clin Gastroenterol Hepatol. 2013;11:839–840.

    Article  CAS  PubMed  Google Scholar 

  38. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428.

    Article  PubMed  Google Scholar 

  39. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 2013;11:832-8 e1–832-8 e2.

    Article  Google Scholar 

  40. Imperiale TF. Sigmoidoscopy screening: understanding the trade-off between detection of advanced neoplasia and diagnostic efficiency. J Natl Cancer Inst. 2013;105:846–848.

    Article  PubMed  Google Scholar 

  41. Jover R, Zapater P, Polania E, et al. Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointest Endosc. 2013;77:381–389.

    Article  PubMed  Google Scholar 

  42. Alvarez C, Andreu M, Castells A, et al. Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointest Endosc. 2013;78:333–341.

    Article  PubMed  Google Scholar 

  43. Bujanda L, Lanas A, Quintero E, et al. Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test. Mayo Clin Proc. 2013;88:683–689.

    Article  CAS  PubMed  Google Scholar 

  44. Bujanda L, Sarasqueta C, Lanas A, et al. Effect of oral anticoagulants on the outcome of faecal immunochemical test. Br J Cancer. 2014;110:1334–1337.

  45. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–1981.

    Article  CAS  PubMed  Google Scholar 

  46. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–696.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101:343–350.

    Article  PubMed  Google Scholar 

  48. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010;362:1795–1803.

    Article  CAS  PubMed  Google Scholar 

  49. Buda A, De Bona M, Dotti I, et al. Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy. Clin Transl Gastroenterol. 2012;3:e6.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Schreiner MA, Weiss DG, Lieberman DA. Proximal and large hyperplastic and nondysplastic serrated polyps detected by colonoscopy are associated with neoplasia. Gastroenterology. 2010;139:1497–1502.

    Article  PubMed  Google Scholar 

  51. Li D, Jin C, McCulloch C, et al. Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am J Gastroenterol. 2009;104:695–702.

    Article  PubMed  Google Scholar 

  52. Hiraoka S, Kato J, Fujiki S, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology. 2010;139:1503–1510, 1510 e1–1510 e13.

  53. Moreira L, Pellise M, Carballal S, et al. High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes. Gut. 2013;62:476–477.

    Article  PubMed  Google Scholar 

  54. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857.

    Article  PubMed  Google Scholar 

  55. Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci. 2010;55:1637–1642.

    Article  CAS  PubMed  Google Scholar 

  56. Mandelli G, Radaelli F, Paggi S, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case–control study. Eur J Gastroenterol Hepatol. 2011;23:323–326.

    Article  CAS  PubMed  Google Scholar 

  57. Levi Z, Rozen P, Hazazi R, et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol. 2009;104:933–938.

    Article  CAS  PubMed  Google Scholar 

  58. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA. 2010;304:2513–2520.

    Article  CAS  PubMed  Google Scholar 

  59. Kaminski MF, Bretthauer M, Zauber AG, et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012;44:695–702.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Ministerio de Economía y Competitividad (SAF2010-19273), the Agència de Gestió d’Ajuts Universitaris i de Recerca (2009 SGR 849), and the Asociación Española contra el Cáncer (Fundación Científica GCB13131592CAST). CIBERehd is funded by the Instituto de Salud Carlos III.

Conflict of interest

Eiken Chemical Co., Ltd., Japan, and its Spanish representatives, Palex Medical and Biogen Diagnóstica, donated supplies and technology used for FIT in the COLONPREV study, but they were not involved in the design of the study or in the analysis or interpretation of results.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Catalonia, Spain

    Antoni Castells

  2. Department of Gastroenterology, Hospital Universitario de Canarias, Tenerife, Spain

    Enrique Quintero

Authors
  1. Antoni Castells
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrique Quintero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoni Castells.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castells, A., Quintero, E. Programmatic Screening for Colorectal Cancer: The COLONPREV Study. Dig Dis Sci 60, 672–680 (2015). https://doi.org/10.1007/s10620-014-3446-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3446-2

Keywords

Search

Navigation